![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
Stroke prevention |
Prostate Cancer |
Free Subscription
1 AJR Am J Roentgenol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Prostate Cancer is free of charge.
Diagnostic Yield of Incremental Biopsy Cores and Second Lesion Sampling for
In-Gantry MRI-Guided Prostate Biopsy.
AJR Am J Roentgenol. 2021;217:908-918.
PubMed
Abstract available
Focal irreversible electroporation for treatment of primary and radio-recurrent
prostate cancer - the evidence is mounting!
BJU Int. 2023 Mar 6. doi: 10.1111/bju.15987.
PubMed
Development and validation of a survival nomogram and calculator for male
patients with metastatic castration-resistant prostate cancer treated with
abiraterone acetate and/or enzalutamide.
BMC Cancer. 2023;23:214.
PubMed
Abstract available
A phase II randomized trial of metastasis-directed therapy with alpha emitter
radium-223 in men with oligometastatic castration-resistant prostate cancer
(MEDAL).
BMC Urol. 2023;23:33.
PubMed
Abstract available
LSD1 inhibition disrupts super-enhancer driven oncogenic transcriptional programs
in castration-resistant prostate cancer.
Cancer Res. 2023 Mar 6:CAN-22-2433. doi: 10.1158/0008-5472.CAN-22-2433.
PubMed
Abstract available
Combined forced diuresis and late acquisition on [(68)Ga]Ga-PSMA-11 PET/CT for
biochemical recurrent prostate cancer: a clinical practice-oriented study.
Eur Radiol. 2023 Mar 9. doi: 10.1007/s00330-023-09516.
PubMed
Abstract available
Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis
Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary
Analysis of the COU-AA-302 Trial.
Eur Urol. 2023 Mar 7:S0302-2838(23)02626-X. doi: 10.1016/j.eururo.2023.
PubMed
Abstract available
Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry
Polygenic Risk Score Associated with Aggressive Disease in Men of African
Ancestry.
Eur Urol. 2023 Feb 27:S0302-2838(23)02561-7. doi: 10.1016/j.eururo.2023.
PubMed
Abstract available
Re: Continuous Enzalutamide After Progression of Metastatic Castration-resistant
Prostate Cancer Treated with Docetaxel (PRESIDE): An International, Randomised,
Phase 3b Study.
Eur Urol. 2023 Mar 2:S0302-2838(23)02630-1. doi: 10.1016/j.eururo.2023.
PubMed
Limited Relevance of the Very Low Risk Prostate Cancer Classification in the
Modern Era: Results from a Large Institutional Active Surveillance Cohort.
Eur Urol. 2023 Mar 2:S0302-2838(23)02622-2. doi: 10.1016/j.eururo.2023.
PubMed
Abstract available
Reprint of: de novo neuroendocrine features in prostate cancer.
Hum Pathol. 2023 Mar 7:S0046-8177(23)00037-0. doi: 10.1016/j.humpath.2023.
PubMed
Abstract available
A Randomised Feasibility Trial of Stereotactic Prostate Radiotherapy with or
without Elective Nodal Irradiation in High-Risk Localised Prostate Cancer (SPORT
Trial).
Int J Radiat Oncol Biol Phys. 2023 Mar 7:S0360-3016(23)00217.
PubMed
Abstract available
Clinical Implementation of (177)Lu-PSMA-617 in the United States: Lessons Learned
and Ongoing Challenges.
J Nucl Med. 2023;64:349-350.
PubMed
(177)Lu-PSMA SPECT Quantitation at 6 Weeks (dose 2) Predicts Short Progression
Free Survival for Patients Undergoing Lu PSMA I&T Therapy.
J Nucl Med. 2022 Sep 8. pii: jnumed.122.264677. doi: 10.2967/jnumed.122.264677.
PubMed
Abstract available
Preoperative Circulating 11-Oxygenated Androgens Are Associated With
Metastasis-free Survival in Localized Prostate Cancer.
J Urol. 2023;209:815.
PubMed
US lawmakers call on Biden Administration to lower the price of enzalutamide.
Lancet Oncol. 2023;24:206.
PubMed
Prostate lesion segmentation based on a 3D end-to-end convolution neural network
with deep multi-scale attention.
Magn Reson Imaging. 2023;99:98-109.
PubMed
Abstract available
Immunoproteasome inhibition in CRPC.
Nat Rev Urol. 2023;20:130.
PubMed
Vaccines as treatments for prostate cancer.
Nat Rev Urol. 2023 Mar 6:1-16. doi: 10.1038/s41585-023-00739.
PubMed
Abstract available
Chaperone-mediated autophagy promotes PCa survival during ARPI through selective
proteome remodeling.
Oncogene. 2023;42:748-758.
PubMed
Abstract available
TRIM28 promotes luminal cell plasticity in a mouse model of prostate cancer.
Oncogene. 2023 Mar 8. doi: 10.1038/s41388-023-02655.
PubMed
Abstract available
CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling
pathway.
Oncol Rep. 2021;45:921-932.
PubMed
Abstract available
Use of miR‑145 and testicular nuclear receptor 4 inhibition to reduce
chemoresistance to docetaxel in prostate cancer.
Oncol Rep. 2021;45:963-974.
PubMed
Abstract available
Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate
cancer based on evolutionary dynamics.
PLoS One. 2023;18:e0282646.
PubMed
Abstract available
GSTP1 positive prostatic adenocarcinomas are more common in Black than White men
in the United States.
PLoS One. 2021;16:e0241934.
PubMed
Abstract available
Exploring the diagnostic potential of adding T2 dependence in diffusion-weighted
MR imaging of the prostate.
PLoS One. 2021;16:e0252387.
PubMed
Abstract available
Estrogen receptor beta and treatment with a phytoestrogen are associated with
inhibition of nuclear translocation of EGFR in the prostate.
Proc Natl Acad Sci U S A. 2021;118:e2011269118.
PubMed
Abstract available
Patient-reported functional outcomes and oncological control after primary focal
cryotherapy for clinically significant prostate cancer: A Phase II mandatory
biopsy-monitored study.
Prostate. 2023 Mar 9. doi: 10.1002/pros.24517.
PubMed
Abstract available
The role of multiparametric magnetic resonance in active surveillance of a
low-risk prostate cancer cohort from clinical practice.
Prostate. 2023 Mar 9. doi: 10.1002/pros.24515.
PubMed
Abstract available
Cardiovascular outcomes among patients with castration-resistant prostate cancer:
A comparative safety study using US administrative claims data.
Prostate. 2023 Mar 6. doi: 10.1002/pros.24510.
PubMed
Abstract available
An Enhancing Renal Mass in Metastatic Prostate Cancer.
Urology. 2023 Mar 7:S0090-4295(23)00203-0. doi: 10.1016/j.urology.2023.
PubMed
Thank you for your interest in scientific medicine.
This policy is made possible thanks to
a media sponsorship by